Tim Kelly compensation by year
Caribou Biosciences Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $475,000 |
| Bonus | $241,250 |
| Option awards | $1,183,320 |
| All other | $13,800 |
| Total | $1,913,370 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Caribou Biosciences, Inc. DEF 14A filed April 25, 2025, accession 0001619856-25-000031, and prior-year filings.
How this page was built: the Caribou Biosciences, Inc. filed document, accession 0001619856-25-000031. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.
Caribou Biosciences’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Rachel Haurwitz | President and chief executive officer | $4,213,245 |
| Tim Kelly · this page | Chief technology officer | $1,913,370 |
| Barbara McClung | Chief legal officer | $1,612,819 |
| Steven Kanner | Chief scientific officer | $1,612,819 |
The full Caribou Biosciences compensation record
free company briefThis page is one person within Caribou Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Caribou Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.